BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Z, Zhang K, Lin S, Mi D, Cao N, Wen Z, Li Z. Radiofrequency ablation combined with percutaneous ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis. International Journal of Hyperthermia 2017;33:237-46. [DOI: 10.1080/02656736.2016.1237681] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Morhard R, Mueller JL, Tang Q, Nief C, Chelales E, Lam CT, Alvarez DA, Rubinstein M, Katz DF, Ramanujam N. Understanding Factors Governing Distribution Volume of Ethyl Cellulose-Ethanol to Optimize Ablative Therapy in the Liver. IEEE Trans Biomed Eng 2020;67:2337-48. [PMID: 31841399 DOI: 10.1109/TBME.2019.2960049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chang YJ, Chen LJ, Chang YJ, Chen PD. Population-based matching comparison between radiofrequency ablation and percutaneous ethanol or acetic acid injection for hepatocellular carcinoma. Eur J Surg Oncol 2020;46:1703-10. [PMID: 32475629 DOI: 10.1016/j.ejso.2020.04.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cui W, Xu R, Wang Y, Shi F, Li J, Chen X. Percutaneous endobiliary radiofrequency ablation and stents in management of hepatocellular carcinoma with bile duct tumor thrombus: Initial single-institution experience. Asia Pac J Clin Oncol 2020;16:259-65. [PMID: 32368843 DOI: 10.1111/ajco.13330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Li Z, Li Q, Wang X, Chen W, Jin X, Liu X, Ye F, Dai Z, Zheng X, Li P, Sun C, Liu X, Zhang Q, Luo H, Liu R. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2021. [PMID: 34655179 DOI: 10.1002/cam4.4350] [Reference Citation Analysis]
5 Liu B, Long J, Wang W, Huang T, Xie X, Chen S, Huang G, Jiang C, Ye J, Long H, Xie X, Kuang M. Predictive factors of treatment outcomes after percutaneous ablation of hepatocellular carcinoma in the caudate lobe: a retrospective study. BMC Cancer 2019;19:699. [PMID: 31311502 DOI: 10.1186/s12885-019-5881-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
6 Lassandro G, Picchi SG, Bianco A, Di Costanzo G, Coppola A, Ierardi AM, Lassandro F. Effectiveness and safety in radiofrequency ablation of pulmonary metastases from HCC: a five years study. Med Oncol. 2020;37:25. [PMID: 32166529 DOI: 10.1007/s12032-020-01352-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Cui W, Wang Y, Fan W, Lu M, Zhang Y, Yao W, Li J. Comparison of intraluminal radiofrequency ablation and stents vs. stents alone in the management of malignant biliary obstruction. Int J Hyperthermia 2017;33:853-61. [PMID: 28540797 DOI: 10.1080/02656736.2017.1309580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Long H, Zhuang B, Huang G, Li X, Lin M, Long J, Xie X, Liu B. Safety and Local Efficacy of Laser Ablation for the Extrahepatic Metastasis of Hepatocellular Carcinoma: An Available Treatment Strategy. Coatings 2020;10:951. [DOI: 10.3390/coatings10100951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Percutaneous ethanol injection for liver metastases. Cochrane Database Syst Rev 2020;2:CD008717. [PMID: 32017845 DOI: 10.1002/14651858.CD008717.pub3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Mu L, Sun L, Pan T, Lyu N, Li S, Li X, Wang J, Xie Q, Deng H, Zheng L, Peng J, Shen L, Fan W, Wu P, Zhao M. Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results. Int J Hyperthermia. 2018;34:59-67. [PMID: 28540809 DOI: 10.1080/02656736.2017.1318332] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
11 Jonas E, Bernon M, Robertson B, Kassianides C, Keli E, Asare KO, Alatise IO, Okello M, Blondel NO, Mulehane KO, Abubeker ZA, Nogoud AA, Nashidengo PR, Chihaka O, Tzeuton C, Dusheiko G, Sonderup M, Spearman CW. Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00042-5] [Reference Citation Analysis]
12 Hwang S, Wook-Seo J, Hoon-Lee B, Hyun-Bae S, Kyung-Lee Y. Percutaneous radiofrequency ablation for hepatic tumors: factors affecting baseline impedance. Diagn Interv Radiol 2021;27:386-93. [PMID: 34003126 DOI: 10.5152/dir.2021.19605] [Reference Citation Analysis]
13 Cornelis FH, Solomon SB. Treatment of Primary Liver Tumors and Liver Metastases, Part 2: Non-Nuclear Medicine Techniques. J Nucl Med 2018;59:1801-8. [PMID: 30361378 DOI: 10.2967/jnumed.116.186379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]